12 Grants
2020
Epigenetic mechanisms of drug resistance in renal cell carcinoma
Haas, Naomi B⋅Hollenhorst, Peter C and Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA224342-03), $406,936USD, 2018-02-01 -- 2023-01-31
2019
Epigenetic mechanisms of drug resistance in renal cell carcinoma
Haas, Naomi B⋅Hollenhorst, Peter C and Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA224342-02), $417,407USD, 02/01/2018 -- 01/31/2023
 
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA213977-03), $139,732USD, 06/15/2017 -- 05/31/2020
 
Immunomodulation by dietary protein restriction
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA221942-02), $198,966USD, 09/13/2018 -- 08/31/2020
2018
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA213977-02), $25,595USD, 06/15/2017 -- 05/31/2020
 
Immunomodulation by dietary protein restriction
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA221942-01A1), $183,372USD, 09/13/2018 -- 08/31/2020
2017
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA213977-01A1), $203,580USD, 06/15/2017 -- 05/31/2019
2010
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA135321-03), $341,073USD, 09/18/2008 -- 07/31/2014
2009
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA135321-02), $336,830USD, 09/18/2008 -- 07/31/2011
2008
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA135321-01A1), $337,432USD, 09/18/2008 -- 12/19/2008
 
Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA121590-02), $249,280USD, 04/24/2007 -- 03/31/2009
2007
Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer
Pili, Roberto
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA121590-01A2), $249,090USD, 04/24/2007 -- 03/31/2009